Get started
MODERNA INCMODERNA INCMODERNA INC

MODERNA INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

MRNA trade ideas

$MRNA Bearish to Bullish Reversal NASDAQ:MRNA Bearish to Bullish Reversal A "Bearish to Bullish Reversal" in technical analysis for NASDAQ:MRNA suggests a shift in the stock's price movement pattern from a downward trend (bearish) to an upward trend (bullish). This reversal typically occurs after a period of decline, indicating that the stock may be transitioning from a bearish phase to a bullish phase. It could signify a potential turning point in market sentiment, with investors becoming more optimistic about the stock's future prospects. Traders often look for confirmation signals to validate this reversal, such as increased trading volume or positive fundamental developments in the company.
NASDAQ:MRNALong
by AlgoTradeAlert
Moderna Surge as it Dives into Promising Cancer Vaccine TrialsModerna ( NASDAQ:MRNA ), a biotechnology company at the forefront of mRNA technology, is experiencing a significant surge in its stock price, climbing over 10% to surpass the $114 per share mark. This rally marks Moderna's highest level since January, reflecting a remarkable turnaround from its challenges in 2023. The resurgence of Moderna's stock can be attributed to several key factors that are igniting investor enthusiasm and confidence in the company's future prospects. One of the primary catalysts driving Moderna's stock rally is the initiation of a mid-stage clinical trial for its experimental cancer vaccine targeting cutaneous squamous cell carcinoma, a prevalent form of skin cancer. This groundbreaking trial, conducted in collaboration with Merck, underscores Moderna's commitment to pioneering innovative solutions in oncology. In addition to advancements in oncology, Moderna ( NASDAQ:MRNA ) continues to make significant strides in addressing infectious diseases, oncology, and rare diseases. Despite the challenges posed by the endemic market, Moderna ( NASDAQ:MRNA ) reported notable pipeline advancements in its fourth-quarter results. The company anticipates initial regulatory approvals for its RSV vaccine (mRNA-1345) starting in the first half of 2024, further bolstering its position in the market. Moreover, Moderna ( NASDAQ:MRNA ) remains optimistic about its COVID-19 franchise, projecting profitability in anticipated sales scenarios for 2024 and beyond. With approximately $4 billion in product sales expected in 2024, primarily driven by COVID-19 vaccine sales and the launch of its RSV vaccine, Moderna is poised for robust growth in the coming years. Technical Analysis Shares of Moderna ( NASDAQ:MRNA ) is exhibiting a bullish Flag pattern indicating the NASDAQ:MRNA has reacted to the Promising Cancer Vaccine Trials news. With a moderate Relative Strength Index (RSI) of 68.74 NASDAQ:MRNA shares is gaining momentum. Looking ahead, Moderna's pipeline update revealed a promising outlook, with 45 therapeutic and vaccine programs, nine of which are in late-stage development. Notably, the Phase 3 trial of its combination vaccine against seasonal flu and COVID-19 has been fully enrolled, with data expected in 2024. These developments underscore Moderna's commitment to innovation and its potential to deliver groundbreaking therapies to address critical unmet medical needs. In conclusion, Moderna's recent stock rally reflects growing optimism and confidence in the company's innovative pipeline, particularly in the areas of oncology and infectious diseases. With promising clinical trials underway and a robust portfolio of vaccine candidates, Moderna is well-positioned to capitalize on emerging market opportunities and drive long-term value for investors. As the company continues to make strides in pioneering mRNA technology, investors can expect Moderna to remain at the forefront of medical innovation, potentially revolutionizing the treatment landscape for various diseases, including cancer.
NASDAQ:MRNALong
by DEXWireNews
Pharmaceutical Giants Stocks: Macro Fib SchematicsThe biggest pharma giants are easy to recognize. Johnson and Johnson, Pfizer, Moderna, Merck & Co, Danaher Corp, Thermo Fisher Scientific. All medications and pharmaceutical drugs come out of these drug corporations. Lab equipment, medical research, vaccines, and other life science developments come out of these conglomerate pharma giants. Support and Resistance is clear with these schematics. All clusters are laid over appropriately.
NASDAQ:MRNA
by MichaelBsul
MRNA- a vaccine biotechnology stock LONGMRNA focuses on vaccine research and development and we are in the flu season an COVID is lurking in the shadows and trying to make a comback. It had an excellent earnings report and forward guidance. On the 60 minute chart, price has bounced up from a test of the anchored VWAP and is at the level of the first upper VWAP while in side the high volume area of the volume profile. The RSI is in the 60s. Bullish momentum is obvious. I will add to my ongoing position here and again the next time I see a dip on the 15-30-minute chart. I look forward to take a piece out of the position after the next earnings report in about 75 days. I have an alert for relative volume when the running mean is exceeded on the 30 minute chart which notify me to take a look at the chart. This is illustrated on this longer time frame chart about the days around earnings but occurs from time to time from other events. As an aside, if NVAX gets weak and develops fundamental challenges. MRNA is a potential rich uncle and could be the leading candidate to do a takeover, friendly or otherwise.
NASDAQ:MRNALong
by AwesomeAvani
Moderna's Surprising Profit Signals Post-Pandemic PivotModerna ( NASDAQ:MRNA ), the pioneering vaccine maker, reported a surprise fourth-quarter profit, sending ripples of optimism through the market. Bolstered by unexpected revenue and strategic cost-cutting measures, the company's resilience amid shifting tides in the pharmaceutical landscape has drawn both attention and applause. Unveiling the Numbers: Moderna's ( NASDAQ:MRNA ) fourth-quarter profit stood at a commendable $217 million, or 55 cents a share, defying analyst expectations of a substantial loss. This unexpected triumph was fueled by a combination of factors, including unforeseen deferred revenue and a strategic overhaul in manufacturing operations. The company's ability to navigate challenges and adapt swiftly underscores its agility and forward-thinking approach. Navigating the COVID-19 Landscape: While Moderna's COVID-19 vaccine continues to be its flagship product, generating substantial revenue, the company is strategically diversifying its portfolio. Despite a decline in COVID vaccine sales from 2022 to 2023, Moderna ( NASDAQ:MRNA ) remains steadfast in its commitment to innovation. The imminent approval decision for its respiratory syncytial virus (RSV) shot marks a significant milestone in this diversification strategy, offering a glimpse into the company's post-pandemic roadmap. Looking Beyond COVID: Moderna's ( NASDAQ:MRNA ) ambitious roadmap extends far beyond the realm of COVID-19. With plans to launch its RSV shot in key markets and a robust pipeline of experimental shots targeting influenza, cancer, and cytomegalovirus, the company is poised for a transformative journey. Despite concerns over efficacy declines compared to rival offerings, Moderna's ( NASDAQ:MRNA ) unwavering focus on research and development signals a bold leap into uncharted territories. International Endeavors: Moderna's ( NASDAQ:MRNA ) participation in the EU Health Emergency and Response Authority’s tendering procedure underscores its commitment to global health initiatives. By prioritizing key international markets and aligning with strategic partners, the company aims to broaden its reach and impact. The forthcoming decision on the EU tender is poised to shape the company's trajectory in the global arena, setting the stage for future collaborations and expansions. Charting the Course Ahead: As Moderna ( NASDAQ:MRNA ) reaffirms its 2024 forecast amidst shifting market dynamics, the company remains steadfast in its pursuit of excellence. With a projected $4 billion in sales and a focus on operational execution, Moderna ( NASDAQ:MRNA ) is poised to navigate challenges and seize opportunities in the years ahead. Conclusion: Moderna's ( NASDAQ:MRNA ) unexpected profit surge and strategic roadmap offer a compelling narrative of resilience and innovation in a rapidly evolving landscape. With eyes set on new horizons and a steadfast resolve, Moderna ( NASDAQ:MRNA ) emerges as a beacon of hope in the post-pandemic world.
NASDAQ:MRNALong
by DEXWireNews
Moderna Inc trading idea (10/01/2024)Analysts at the Oppenheimer brokerage company, as reported by Reuters , have upgraded the stock rating of Moderna Inc. to "outperforming the market," and the vaccine maker's CEO reiterated the company's goal of achieving sales growth by 2025. The issuer's shares fell nearly 45% in 2023, marking its worst annual performance due to weak COVID-19 vaccine sales. According to Oppenheimer, Moderna could have five products on the market by 2026. So, today, we will examine the Moderna Inc. (NASDAQ: MRNA) stock chart. On the D1 timeframe, there is a "break" in the downward trend, which has persisted since the end of 2022. Resistance has formed at 115.81, with support at 97.91. Currently, an upward trend is developing on the chart. On the H1 timeframe, if there is a rebound from the 100.98 level, the short-term target for a price increase can be set at 115.81, while in the medium term, it could hover around 139.77. — Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews. The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments. Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 66.02% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
NASDAQ:MRNA
by RoboMarkets
Riding the Wave: The Bullish Case for MRNA’s Inverted Scallop In the dynamic world of stock trading, there are some patterns which emerge that tell a story of market sentiment, investor behavior, and potential future movements. One such narrative is unfolding with Moderna Inc. (MRNA), where an intriguing pattern has caught my eye as we've seen a price rebound since November 2nd, 2023, the inverted scallop. The inverted scallop is not a well known pattern, but renowned candle expert Thomas Bulkowski identifies it as an important one. You can see what Bulkowski says about this pattern here: thepatternsite.com The Inverted Scallop: A Sign of Reversal The inverted scallop pattern, resembling a reverse ‘J’, is a bullish reversal pattern that signals a potential shift in momentum. For MRNA, this pattern began to form after a long-term downtrend, with the stock plummeting from a high of $456.76 to a low of $71.23. However, the tide seems to be turning, with the price curving upwards in a recovery that mirrors the shape of an inverted scallop shell. Bulkowski shows an example of this pattern with the price action of Boeing in 2005. It bares a striking resemblance to what we are seeing with MRNA today. Confirming the Pattern with Technical Indicators While the scallop pattern itself is compelling, confirmation from other technical indicators is crucial for a robust bullish thesis: - Divergence: The presence of bullish divergence, where the price hits a lower low while an oscillator forms a higher low, suggests that the downtrend is losing steam. - Chaikin Money Flow (CMF): A positive CMF value during the formation of the scallop pattern indicates buying pressure and accumulation, reinforcing the bullish outlook. - Resistance Breakout: A key factor for the pattern’s confirmation is the breakout above significant resistance levels. For MRNA, breaking past the resistance zone between $86.02 and $87.11, as well as subsequent levels at $89.90 and $97.28, would validate the reversal. Market Psychology: Reading Between the Lines The long-term downtrend followed by the inverted scallop pattern reflects a shift in market psychology. Initially driven by fear, the potential reversal indicates a change towards optimism, as investors begin to recognize value and anticipate a positive future for MRNA. We see this in the fundamental analysis of MRNA with the news of their recent success in phase 2 studies on cancer vaccines. Conclusion: A New Chapter for MRNA? As MRNA’s price action paints a picture of recovery, the inverted scallop pattern offers hope for the continuation of a bullish reversal. Supported by technical indicators and a change in market sentiment, the narrative suggests that MRNA could be on the cusp of a new chapter.
NASDAQ:MRNALong
by jkish19871
2
Moderna's Road to Recovery Moderna has recently garnered attention for its significant rebound after a challenging 2023. The biotech company, primarily known for its groundbreaking COVID-19 vaccine, is poised for a transformative journey ahead, with a strategic pipeline that extends far beyond pandemic management. This Idea delves into the recent surge in Moderna's stock, the pivotal role of Oppenheimer's upgrade, and the promising prospects that lie ahead. The Resilience of Moderna Stock: Following a tumultuous year in 2023, marked by a 45% dip in stock value, Moderna is experiencing a remarkable resurgence. A recent 15% surge was triggered by Oppenheimer's optimistic upgrade to "outperform." The upgrade reflects the financial firm's confidence in Moderna's ability to diversify its product portfolio, projecting the introduction of five new products by 2026. This shift in sentiment underscores the market's recognition of Moderna's potential to pivot beyond its flagship COVID-19 vaccine. Diversification Beyond COVID-19: Moderna's dependency on COVID-19 vaccine sales took a toll in 2023, prompting the need for diversification. Oppenheimer analyst Hartaj Singh highlights Moderna's promising pipeline, suggesting the potential launch of several products over the next 12 to 18 months. Among these, an experimental vaccine targeting respiratory syncytial virus (RSV) for older adults stands out, with a potential FDA decision in April 2024. The company's experimental flu vaccine, displaying superior immune response in trials, could also secure approval in 2024 or 2025. Additionally, the prospect of an FDA approval for an experimental personalized cancer vaccine further enhances Moderna's growth potential. Financial Outlook and Market Response: Despite a projected dip in COVID-19 vaccine sales in 2024 due to factors like vaccine fatigue, Moderna's overall sales are expected to surge in 2025 and beyond. The company's third-quarter earnings report anticipates revenue to rebound to $4 billion in 2025 after a temporary decline to $4 billion in 2024. Moderna's commitment to launching up to 15 products in the next five years aligns with its goal to diversify revenue streams and minimize reliance on pandemic-related products. Technical Analysis and Investor Sentiment: A crucial aspect of Moderna's recent success lies in its positive technical analysis. Breaking the ceiling of the falling trend in the medium-long term signifies a slower rate of decline. While the stock has met the short-term objective at $86.84, the technical indicators suggest cautious optimism. With support at $70.00 and resistance at $118, the stock appears well-positioned for potential growth. Conclusion Moderna's stock journey reflects a company resilient in the face of challenges, capitalizing on opportunities beyond the pandemic. Oppenheimer's upgrade and the positive technical analysis signal a turning point for Moderna, with a diversified product portfolio offering a hedge against future uncertainties. As the pharmaceutical giant marches towards its goal of launching innovative products, investors are increasingly viewing Moderna as more than just a COVID-19 play, but a promising player in the broader healthcare landscape.
NASDAQ:MRNALong
by DEXWireNews
MODERNAModerna, Inc. is a pharmaceutical and biotechnology company based in Cambridge, Massachusetts. Founded in 2010, it focuses on the development of messenger RNA (mRNA) therapeutics, primarily vaccines. Moderna is a leader in the field of mRNA technology, which uses messenger RNA to instruct cells to produce specific proteins. This technology has revolutionized vaccine development and holds potential for treating various diseases. Beyond COVID-19, Moderna has a robust pipeline of mRNA vaccines and therapeutic candidates in development for various diseases, including influenza, HIV, respiratory syncytial virus, and cancer. In 2023, Moderna achieved several notable milestones, including: 1. Receiving full approval for Spikevax from the U.S. Food and Drug Administration (FDA). 2. Initiating the first-in-human dosing for mRNA-1653, a combination vaccine with the potential to protect against multiple respiratory viruses. 3. Agree with the Chinese government to develop mRNA drugs for exclusive use in China. Moderna plays a vital role in the future of medicine and we are looking at adding the stock to our portfolio. Year to date, the stock is down about 49% and 2024 is looking to be a stable year for Moderna as long as it does not break and trade below support. This will pull the stock price back to its 2019 level.
NASDAQ:MRNALong
by Candles254
2
Moderna’s Stock Boosted by Data From Trial of Melanoma TreatmentModerna Inc.’s stock soared 14% early Thursday to early Friday after the biotech company and partner Merck & Co. announced positive data from a trial of Moderna’s mRNA-4157 in combination with Merck’s blockbuster cancer drug Keytruda in patients with resected high-risk melanoma (stage III/IV). The companies said that after about three years, the combination reduced the risk of recurrence or death by 49% in a Phase 2 trial and the risk of distant metastasis or death by 62%, as compared with Keytruda alone. “As we continue to follow participants in the Keynote-942/mRNA-4157-P201 study, we are excited to see such a robust clinical benefit with mRNA-4157 (V940) as adjuvant treatment in combination with Keytruda in people with resected high-risk melanoma,” said Kyle Holen, senior vice president and head of development in therapeutics and oncology at Moderna. “These data add another positive analysis to the multiple endpoints and subgroups previously assessed in this study,” he said. Technical Analysis NASDAQ:MRNA reached its 1 Month High on the 14th December, 2023 siting the stocks responds to the Positive Data from the Trial of Melanoma Treatment. Moderna’s stock has fallen 50% to date in 2023, while the S&P 500 has gained 22.6%. Although NASDAQ:MRNA is trading near the bottom of its 52-week range and below its 200-day simple moving average, the stock is likewise showing signs of a continual trend which is poise to set foot on a new Resistance level.
NASDAQ:MRNALong
by DEXWireNews
2
MODERNAWhat's going on with Moderna? It's falling so hard Company Discussion I know that the Covid vaccine "growth" doesn't work either for Moderna or for Pfizer. Also, I read that their co-founder has sold more shares recently. However, they are working on many more new drugs. Were heading below until new variant of virus being spread by this company. what is your thought? not buying this scam of stocks. would you? or you woke enough to understand their just a money graber on the first place
NASDAQ:MRNA
by D1GITALTRADES
6
MRNA no brainer buyBack to MRNA. Big misunderstanding or lack of homework by the market. US market is only 1/3 if sales. Clients are governments worldwide that order guaranteed doses as insurances. Some contracts APA are for 10 years ( even SAAS are not priced on 10 years visibility ). Last but not least. The price for a 1 dosis ( now packaged in a 1 shot syringe) is not anymore 20 usd. But 120 ! Costs of sales this year is high because of production adjustment to the new packaging. But next year back to 70% + growth margin. The rest of the 50 products pipeline is FREE. This is the steal of the year for anyone willing to do the work.
NASDAQ:MRNALong
by model421
1